Intellia Therapeutics (NTLA) Projected to Post Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Intellia Therapeutics to announce earnings of ($0.7970) per share and revenue of $9.74 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting analysts’ consensus estimates of ($0.80). The firm had revenue of $7.66 million for the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The company’s revenue was down 46.4% on a year-over-year basis. During the same period last year, the firm posted ($0.98) EPS. On average, analysts expect Intellia Therapeutics to post ($3.21) EPS for the current fiscal year and ($2.32) EPS for the next fiscal year.

Intellia Therapeutics Stock Down 6.5%

NASDAQ:NTLA opened at $11.66 on Tuesday. Intellia Therapeutics has a 52-week low of $7.95 and a 52-week high of $18.48. The stock has a fifty day simple moving average of $12.21 and a 200-day simple moving average of $13.06.

Wall Street Analysts Forecast Growth

NTLA has been the subject of a number of recent analyst reports. Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, August 25th. Barclays started coverage on shares of Intellia Therapeutics in a report on Tuesday, October 6th. They set an “underweight” rating and a $8.00 price objective for the company. Evercore raised shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 target price for the company in a research report on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have issued a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $20.57.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.

Intellia’s pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.